Top Back to top

Allogeneic stem cell transplantation for refractory AML: a comparison between sequential or standard myeloablative conditioning regimen (a retrospective study).

Study number:
8417018
Short title:
Etude comparative MAC Séqentiels.
Study status:
Ongoing
Deadline for data collection:
 
Study design:
retrospective, multicenter study
Primary objective:
The primary end points are:
• 2 years overal survival OS)
• 2 years disease free survival (DFS)
Death from any cause will be considered as an event. Event will be summarized by a survival curve. Surviving patients will be censored at time of last follow-up.

Comparison of DFS and OS will be performed between patients who received a sequential conditioning and those who received a standard myeloablative conditioning regimen.

Key inclusion criteria:
-Age at transplant below to 18 years.
-Acute myeloide leukemia (without secondary AML or MDS)
- First HSCT
-Refractory disease at transplant (> 5% of marrow blasts at transplant).
- Transplantation between 2000 et 2015
Country:
France
Principal investigator:
Audrey Grain
Principal investigator email:
audrey.grain@aphp.fr
EBMT Study coordinator:
Arnaud Dalissier
Study coordinator email:
arnaud.dalissier@upmc.fr

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to data.protection@ebmt.org